Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 89 for your search:
Cancer Type:
Myeloproliferative disorders (incl. CML)
Stage/Subtype of Cancer:
chronic neutrophilic leukemia
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI, NHLBI
Protocol IDs:
385
, BMT CTN 0402, U01 HL069294-05, NCT00406393
2.
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-1825.00
, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
3.
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-05011-L
, OHSU-210, NCT00245037
4.
Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Older patients
Sponsor:
NCI, Other
Protocol IDs:
BMT124
, 75117, BMT124, NCT00185692, NCT00185692
5.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-065
, X05175, NCT00369226
6.
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
04U.115
, NCT00429416
7.
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PDX-009
, NCT00481871
8.
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
9.
Monoclonal Antibody Therapy, Fludarabine, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Disease
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
10.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
11.
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UPCC 20406
, NCT00674427
12.
Natural Killer Cells and Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2230.00
, 2230.00, IR-6771, NCT00789776
13.
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
VGFT-ST-0708
, TCD10767, NCT00794417
14.
Double Cord Blood Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
Other
Protocol IDs:
CHNY-06-533
, IRB AAAC3457, NCT00801931
15.
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
19 to 75
Sponsor:
NCI
Protocol IDs:
UNMC-16407
, 164-07, NCT00816413
16.
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
9090-03
, NCT00858572
17.
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 and over
Sponsor:
Other
Protocol IDs:
6895
, 2323.00, NCT00867139
18.
Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
8 to 80
Sponsor:
NHLBI
Protocol IDs:
NHLBI-99-H-0050
, NCT00003838
19.
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1898.00
, 5788, NCT00089011
20.
Alemtuzumab, Fludarabine, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1959.00
, 5952, NCT00118352
21.
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
UMCC 2-61
, NCT00143845
22.
Mindfulness Meditation in Bone Marrow Transplantation
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
21 and over
Sponsor:
Other
Protocol IDs:
05-070
, NCT00165282
23.
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
NCI
Protocol IDs:
UCSF-02257
, UCSF-2214, UCSF-H24045-22163-04, NCT00301912
24.
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UMN-2005NT018
, UMN-0506M70866, UMN-MT2005-06, NOVARTIS-CZOL446EUS29, NCT00321932
25.
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
10 to 75
Sponsor:
NHLBI
Protocol IDs:
NHLBI-06-H-0248
, NHLBI-IDE-13058, NCT00398346
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute